U.S. market Closed. Opens in 8 hours 28 minutes

ATOS | Atossa Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ATOS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak.

Valuation (12%)

Company Industry
P/E Ratio (TTM) -7.04 -22.08
PEG Ratio (TTM) -0.56 15.66
P/S Ratio (TTM) 10,130.43 49.38
P/B Ratio (TTM) 2.27 18.85
P/FCF Ratio (TTM) -9.75 -3.07
Price to 5YR AVG Earnings Ratio -1.61 -3.42
Price to 5YR AVG FCF Ratio -15.72 -9.04

Profitability (25%)

Company Industry
ROA (TTM) -30.18% -5.15%
ROE (TTM) -29.18% 16.37%
Net Profit Margin (TTM) -143,944.44% -2,030.32%
ROIC 5YR AVG 31,545.38% 15.65%

Growth (35%)

4QTR AVG 3YR AVG 5YR AVG
EPS 8.21% 41.39% 18.64%
Revenue -25.00% N/A N/A
Net Income 8.36% -23.74% -22.65%
Cash Flow -2.80% -23.66% 0.58%

Health (49%)

Company Industry
Current Ratio (TTM) 14.35 6.19
Quick Ratio (TTM) 14.15 5.91
D/E Ratio (TTM) N/A -15.10
Interest Coverage (TTM) -37.28 -1.60
Piotroski F-Score 2 5
Altman Z-Score 16.03 14.02
LTL to 5YR AVG FCF N/A 0.18
Shares Outstanding Growth 5YR AVG 215.89% 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙